Drug Trial Radar · NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jan 8, 2022
Primary completion
Apr 21, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions
Zilovertamab vedotinBiological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per Lugano Response CriteriaTime frame: Up to approximately 50 months
Locations
71 sites in 17 countries. Site status is shown where the registry gives one.
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229)
Orange, California
Innovative Clinical Research Institute ( Site 0202)
Whittier, California
Georgetown University Medical Center ( Site 0204)
Washington D.C., District of Columbia
Northside Hospital ( Site 0206)
Atlanta, Georgia
University of Chicago Medical Center ( Site 0207)
Chicago, Illinois
Franciscan St. Francis Health ( Site 0225)
Indianapolis, Indiana
University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211)
Baltimore, Maryland
Massachusetts General Hospital-Cancer Center Protocol Office ( Site 0203)
Boston, Massachusetts
University of Michigan ( Site 0200)
Ann Arbor, Michigan
Karmanos Cancer Institute ( Site 0216)
Detroit, Michigan
Saint Louis University Cancer Center ( Site 0209)
St Louis, Missouri
Atlantic Health System Morristown Medical Center ( Site 0213)
Morristown, New Jersey
New York Medical College ( Site 0215)
Valhalla, New York
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217)
Cincinnati, Ohio
University Hospitals Cleveland Medical Center ( Site 0222)
Cleveland, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
Columbus, Ohio
AHN West Penn Hospital ( Site 0212)
Pittsburgh, Pennsylvania
Avera Cancer Institute- Research ( Site 0233)
Sioux Falls, South Dakota
MEDICAL COLLEGE OF WISCONSIN ( Site 0234)
Milwaukee, Wisconsin
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0100)
Toronto, Ontario, Canada
James Lind Centro de Investigación del Cáncer ( Site 2705)
Temuco, Araucania, Chile
Clínica Alemana de Santiago ( Site 2704)
Santiago, Region M. de Santiago, Chile
Beijing Cancer hospital ( Site 2900)
Beijing, Beijing Municipality, China
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal Medicine ( Site 2907)
Guangzhou, Guangdong, China
Henan Cancer Hospital-hematology department ( Site 2903)
Zhengzhou, Henan, China
Wuhan Union Hospital ( Site 2906)
Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 2905)
Changsha, Hunan, China
The First Hospital of Jilin University-Hematology ( Site 2910)
Changchun, Jilin, China
Fudan University Shanghai Cancer Center ( Site 2908)
Shanghai, Shanghai Municipality, China
Shanghai East Hospital ( Site 2902)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University-Head and Neck Oncology ( Site 2911)
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital-lymphoma ( Site 2901)
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University-Bone marrow transplant centre ( Site 2912)
Hangzhou, Zhejiang, China
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0801)
Prague, Czechia
Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0800)
Brno, Brno-mesto, Czechia
North Estonia Medical Centre Foundation ( Site 0900)
Tallinn, Harju, Estonia
Pitie Salpetriere University Hospital-Clinical haematology ( Site 1000)
Paris, France
Centre Hospitalier de la Côte Basque ( Site 1002)
Bayonne, Aquitaine, France
Evangelismos General Hospital of Athens ( Site 1214)
Athens, Attica, Greece
General Hospital of Athens "Laiko"-Hematology Department ( Site 1213)
Athens, Attica, Greece
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.